<DOC>
	<DOCNO>NCT00001437</DOCNO>
	<brief_summary>After initial assessment condition specify clinical laboratory parameter , patient treat 8 week standard pentoxifylline dose ( 400 mg po TID ) . Objective subjective response parameter re-assessed end treatment 8 week later possible decay response .</brief_summary>
	<brief_title>Trial Pentoxifylline Patients With Functional Disability Caused Radiation-Induced Advanced Regional Fibrosis</brief_title>
	<detailed_description>Patients late fibrovascular sequela radiation combine radiation surgery , quantifiable symptomatology disability , eligible trial . This protocol design open label one arm study . ( A placebo control randomized trial approve IRB extensive negotiation , drug placebo slow release formulation provide manufacturer ) . Up fifty patient recruit . After initial assessment condition specify clinical laboratory parameter , patient treat 8 week standard pentoxifylline dose ( 400 mg po TID ) . Objective subjective response parameter re-assessed end treatment 8 week later possible decay response . In addition symptomatic objective subjective response , blood urine collect TNF , TGF-beta , FGF . Cutaneous blood flow collagen subtyping perform subset patient use Laser Doppler , functional MRI technique subcutaneous tissue biopsy . We examine correlation clinical response biological response .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>POPULATION CHARACTERISTICS : Regional advance postradiation fibrosis neck , chest wall , pelvis , extremity cause measurable impairment specific function , i.e . : Decreased range motion , Weakness , Sensory deficit , Pain require narcotic , Significantly altered activity daily live . None condition present either radiotherapy attribute surgery chemotherapy . Patients prostate cancer allow prostatespecific antigen ( PSA ) less 4.0 ng/mL last 3 PSA value stable decrease . Abnormal bone scan film acceptable consistent degenerative disease . No recurrent metastatic cancer . No concurrent second cancer . PRIOR/CONCURRENT THERAPY : At least 3 month since pentoxifylline . PATIENT CHARACTERISTICS : Age : 18 . Performance status : Karnofsky 70 % 100 % ( unrelated postradiation fibrosis ) . CARDIOVASCULAR : No symptomatic coronary artery disease frequent anginal episode necessitate follow past 6 month : Coronary artery bypass , Angioplasty , Pacemaker placement , Thrombolytic treatment . No chronic cardiac failure persistent hemodynamic abnormality ejection fraction le 40 % . No coagulation , platelet , vascular disorder threatens cause bleeding . OTHER : No intolerance pentoxifylline xanthine ( e.g. , caffeine , theophylline , theobromine ) . No seizure disorder . No peptic ulcer disease . Willing undergo serial evaluation ( exclude biopsy , laser Doppler , MRI ) NCI rehabilitation specialist documentation grade functional disability . No pregnant nursing woman . Adequate contraception encourage fertile woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Cytokines</keyword>
	<keyword>Fibrosis Intensity</keyword>
	<keyword>Post-Radiation Fibrosis</keyword>
	<keyword>Radiation Injury</keyword>
	<keyword>Trental</keyword>
</DOC>